Skip to main content
Year archive

ALK-Abelló — 2026 filings

All 19 regulatory filings released by ALK-Abelló (ALK) in 2026, sourced directly from the official regulator.

19 Filings
2026 Period
2026 filings (19)
Filing Released Lang
ALK upgrades its full-year outlook
Regulatory Filings
2026-05-04 Danish
ALK upgrades its full-year outlook
Regulatory Filings
2026-05-04 Danish
ALK upgrades its full-year outlook
Regulatory Filings
2026-05-04 English
ALK upgrades its full-year outlook
Regulatory Filings
2026-05-04 English
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy
Regulatory Filings
2026-04-20 Danish
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy
Regulatory Filings
2026-04-20 Danish
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy
Regulatory Filings
2026-04-20 English
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy
Regulatory Filings
2026-04-20 English
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
Director's Dealing
2026-04-08 Danish
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
Director's Dealing
2026-04-08 Danish
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
Director's Dealing
2026-04-08 English
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
Director's Dealing
2026-04-08 English
Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin
Annual Report (ESEF) FY 2025
2026-02-20 English
Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin
Annual Report FY 2025
2026-02-20 English
Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin
Earnings Release FY 2025
2026-02-20 English
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children
Regulatory Filings
2026-01-29 Danish
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children
Regulatory Filings
2026-01-29 Danish
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children
Regulatory Filings
2026-01-29 English
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children
Regulatory Filings
2026-01-29 English